Traditional Chinese medicine for irritable bowel syndrome: A protocol for meta-analysis.
Traditional Chinese medicine for irritable bowel syndrome: A protocol for meta-analysis.
复制标题
肠易激综合症的传统中药：荟萃分析的方案。
DOI：
10.1097/md.0000000000023394
复制
发表时间：
2020-11-25
期刊：
影响因子：
1.6
通讯作者：
Feng PM
中科院分区：
文献类型：
--
作者：
Yao CJ;Li YL;Pu MJ;Luo LH;Feng PM
肠易激综合征（Irritable bowel syndrome，IBS）是一种常见的功能性胃肠道疾病，以反复发作的腹痛、腹部不适及腹泻、便秘等排便习惯异常为特征，两者或交替出现。虽然IBS不致命，但它严重影响患者的日常生活和工作。西药如抗消化道溃疡药、胃肠道解痉药等往往不能取得满意的疗效。然而，大量的随机对照试验表明，中医药治疗IBS的疗效非常令人满意。虽然中医药在临床上得到了广泛的应用，但其相对有效性和安全性尚未得到证实。因此，本研究将采用荟萃分析来验证不同类型中药治疗IBS的有效性和安全性。我们检索了中国知网、万方数据库、中国科技期刊数据库、中国生物医学文献数据库、Pubmed、Embase、Web of Science和科克伦图书馆，以查找自2020年10月15日开始至2020年10月15日期间中医药治疗IBS的所有随机对照试验。两位作者将根据预先设计的纳入和排除标准独立选择研究，提取数据。将使用科克伦偏倚风险工具评估方法学质量评估和偏倚风险。所有数据分析将使用Revman5.3、WinBUGS 1.4.3和Stata14.2软件进行。本研究将直接和间接地比较各种研究的不同结局指标，并提供不同中医方法治疗IBS患者的有效性和安全性的高质量综合。主要结局指标包括疗效、缓解率（无药物症状）、复发率、临床绝对评分和相对评分。次要观察指标包括相关不良反应和血清5-羟色胺浓度。本系统评价的结论将为中医药治疗IBS的有效性和安全性提供高质量的证据。本研究方案已通过方案登记处获得资助。注册号为INPLASY 2020100052
Irritable bowel syndrom (IBS) is a common functional gastrointestinal disorder which is characterized as recurrent abdominal pain, abdominal discomfort, and abnormal bowel habits such as diarrhea, constipation, both or alternate appear. Although IBS is not fatal, it seriously affects the patients’ daily life and work. Western drug, such as antidiarrheals, gastrointestinal antispasmodic, often cannot get satisfying curative effects. However, the therapeutic effect of Traditional Chinese medicine (TCM) on IBS is very satisfactory which was shown in a large number of randomized controlled trials. Although TCM has been widely used in clinical practice, its relative effectiveness and safety have not been confirmed. Therefore, this study will use meta-analysis to verify the efficacy and safety of different types of TCM in the treatment of IBS. We search the China National Knowledge Infrastructure, Wanfang Database, Chinese Science and Technology Periodical Database, Chinese Biomedical Literature Database, Pubmed, Embase, Web of Science, and the Cochrane library for all randomized controlled trial of TCM for the treatment of IBS from their inception to Oct 15, 2020. Two authors will independently select studies, extract data based on predesigned inclusion and exclusion criteria. Methodological quality assessment and risk of bias will be assessed using Cochrane bias risk tool. All data analysis will be conducted using Revman5.3, WinBUGS 1.4.3, and Stata14.2 software. This study will compare the different outcome indicators of various studies directly and indirectly, and provide a high-quality synthesis of effectiveness and safety of different TCM methods for patients with IBS. The main outcome indicators include effectiveness, remission rate (no drug symptoms), relapse rate, clinical absolute score, and relative score. Secondary outcome indicators included related adverse reactions and serum serotonin concentration. The conclusion of this systematic review will provide a high-quality evidence based on the efficacy and safety of different TCM treatment methods for IBS. This study protocol has been funded through a protocol registry. The registry number is INPLASY2020100052